GlassScriptPhysician profile
Jerome O Carter
NPI 1689698961
$1,262.52
in general payments reported to CMS, 2019-2025
15 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $79.57 · 2023: $175 · 2024: $393 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $480.82 | 2024-2025 | Proclaim |
| Medtronic USA, INC. | $172.77 | 2019-2020 | |
| Forte Bio-Pharma LLC | $125.66 | 2023 | Prolate, Nalocet |
| Collegium Pharmaceutical, INC. | $102.07 | 2019-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.61 | 2020-2024 | Relistor |
| Sentynl Therapeutics, INC. | $77.75 | 2019 | |
| Scilex Pharmaceuticals INC. | $56.81 | 2019 | |
| Boston Scientific Corporation | $30.93 | 2019-2024 | |
| Shionogi INC | $27.78 | 2019 | |
| Indivior INC. | $27.65 | 2025 | Sublocade |
| Ibsa Pharma INC. | $20.96 | 2023 | Tirosint, Licart |
| Vertical Pharmaceuticals, LLC | $16.96 | 2019 | |
| Pfizer INC. | $16.15 | 2019 | |
| Si-Bone, INC. | $13.32 | 2019 | |
| West Therapeutics Development, LLC | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.